Loading
NASDAQHealthcareMedical - Pharmaceuticals
Latest quote
$4.84
+$0.14 · +2.98%
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Previous close
$4.84
+$0.14 · +2.98%
After-hours
$4.84
$0.00 · 0.00%
Sep 11, 7:30 PM ET
Regular session · ET · Market data may be delayed.
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Day range
Current $4.84
52-week range
Current $4.84
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
47
Fair Value
Sentiment
61
Bullish
Risk
72
High Risk
Momentum
26
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
SCYNEXIS, Inc. is a biotechnology company, which engages in the development of novel oral and intravenous triterpenoid antifungal for the treatment of several fungal infections, including vulvovaginal candidiasis, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections. The company was founded by Scot Kevin Huber, Terry Eugene Marquardt, Pierre Bernard Jacques Monnet, Russell J. Outcalt, and Yves Joseph Ribeill on November 4, 1999 and is headquartered in Jersey City, NJ.
Day range
Current $4.84
52-week range
Current $4.84
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Jun 1, 2026 | 1:8 | — | — |
Stock split | Jul 17, 2020 | 1:10 | — | — |
Effective Jun 1, 2026
1:8
Effective Jul 17, 2020
1:10
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.41M0.00%2.3T USD0.03%$376.31+0.82%
Vanguard Extended Market ETFVXF620.46K0.00%93.7B USD0.05%$237.76+0.68%
EA Bridgeway Omni Small-Cap Value ETFBSVO70K—2.45B USD0.45%$29.4578+0.58%
Dimensional - US Small Cap ETFDFAS24.39K0.00%15.49B USD0.26%$80.52+0.64%
U.S. Micro Cap Portfolio ETFDFMC22.71K0.00%7.73B USD0.43%$59.13+0.67%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFEA Bridgeway Omni Small-Cap Value ETFBSVODimensional - US Small Cap ETFDFASU.S. Micro Cap Portfolio ETFDFMCAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
